Paratek’s 2026 TYMLOS Areas of Interest
Paratek supports research in multiple areas for TYMLOS (abaloparatide), including but not exclusive to:
- Osteoporosis Care (disease state, identification, screening, treatment, quality of care, and treatment sequencing)
- Outcomes in Populations not included in clinical trials or with limited existing evidence
- Bone Health Optimization
- Real World Evidence
- Patient-centric outcomes
- Evidence addressing treatment gaps, screening, and treatment initiation across the osteoporosis care pathway
TYMLOS Requests for Drug Product for use in IIR
- The following formulations are available:
- TYMLOS multidose injection pen (80mcg)
- Placebo multidose injection pen
- Abaloparatide API powder
Paratek’s 2026 TYMLOS IIR Review Meeting Schedule:
- July 28, 2026 (Deadline for Submission, July 14, 2026)
- September 29, 2026 (Deadline for Submission, September 15, 2026)
- November 17, 2026 (Deadline for Submission, November 3, 2026)